CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have received a consensus rating of "Moderate Buy" from the nineteen analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, six have given a hold rating, ten h...